SAN FRANCISCO, April 18, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused
on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases,
today announced the pricing of its underwritten public
offering of 5,200,000 shares of its common stock at a price to the
public of $14.50 per share before
underwriting discounts and commission. The gross proceeds to
Audentes from the offering, before deducting the underwriting
discounts and commissions and other offering expenses payable by
Audentes, are expected to be approximately $75.4 million. In addition, Audentes has
granted the underwriters a 30-day option to purchase up to an
additional 780,000 shares of common stock. The offering is expected
to close on April 24, 2017, subject
to customary closing conditions.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running
managers for the offering. Wedbush PacGrow is acting as a
co-manager.
Registration statements relating to these securities have become
effective as of April 18, 2017.
The offering is being made only by means of a prospectus. A copy of
the final prospectus relating to the offering, when available, may
be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte,
NC 28255-0001, Attention: Prospectus Department or by email
at dg.prospectus_requests@baml.com; Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood,
NY 11717 or by telephone at (631) 274-2806; or Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein that do not
describe historical facts, including, but not limited to,
statements regarding the expected gross proceeds and completion of
the offering, are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements. Such
risks and uncertainties include, among others, the risks identified
in Audentes' filings with the SEC, the prospectus related to the
offering, and subsequent filings with the SEC. Any of these
risks and uncertainties could materially and adversely affect
Audentes' results of operations, which would, in turn, have a
significant and adverse impact on Audentes' stock price.
Audentes cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. Audentes undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date they were made or to reflect
the occurrence of unanticipated events.
Audentes Contacts:
Investor Contact:
Thomas Soloway
415-818-1040
ir@audentestx.com
Media Contact:
Jeffrey Gruis
415-818-1015
media@audentestx.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-pricing-of-public-offering-of-common-stock-300441484.html
SOURCE Audentes Therapeutics, Inc.